HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arsenijevic, Y Articles by Dreifuss, J J Search for Related Content PubMed PubMed Citation Articles by Arsenijevic, Y Articles by Dreifuss, J J

Arginine vasopressin (AVP) acts in the pituitary gland, in synergy with corticotrophin-releasing factor, to induce ACTH release in response to stressful stimuli. Pituitary AVP receptors in the rat are coupled to phospholipase C, as are the so-called V₁-type AVP receptors. The present study examined [³H]AVP binding in membranes prepared from the anterior lobe of the pituitary gland of the pig. [³H]AVP, alone or in competition with analogues, bound to sites in the pig anterior lobe which are pharmacologically similar to those described previously by others in the rat pituitary gland. For comparison, the same competition studies were performed on membrane preparations from the rat liver which contain the classic V₁-type AVP receptor. Pituitary and liver AVP-binding sites were dissimilar; both cyclic and linear V₁ antagonists had, in general, a much lower affinity for pituitary AVP-binding sites than for those in the liver. Thus, Phaa-D-Tyr(Et)-Phe-Gln-Asn-Lys-Pro-Arg-NH₂ (Phaa=phenylacetyl) has a 2500-fold greater affinity for the latter (negative logarithm of inhibition constant (pK_i)=9·64) than for the former (pK_i=6·22). One linear antagonist, Pa-D-Tyr-Phe-Val-Asn-Arg-Pro-Arg-Arg-NH₂ (Pa=propionyl) had about equal affinities for liver and pituitary membranes (pK_i=6·39 and 6·53 respectively). Another compound, Phaa-D-Tyr-Phe-Val-Asn-Arg-Pro-Arg-Arg-NH₂ had the highest affinity found to date for binding to AVP sites in the pituitary (pK_i=7·43). These findings suggest some ideas for the design of more potent and/or selective AVP analogues acting in the pituitary gland.

Journal of Endocrinology (1994) 141, 383–391

This article has been cited by other articles:

				M. V. Mikhailova, P. R. Mayeux, A. Jurkevich, W. J. Kuenzel, F. Madison, A. Periasamy, Y. Chen, and L. E. Cornett Heterooligomerization between Vasotocin and Corticotropin-Releasing Hormone (CRH) Receptors Augments CRH-Stimulated 3',5'-Cyclic Adenosine Monophosphate Production Mol. Endocrinol., September 1, 2007; 21(9): 2178 - 2188. [Abstract] [Full Text] [PDF]

				E. R. Gillard, C. G. Coburn, A. de Leon, E. P. Snissarenko, L. G. Bauce, Q. J. Pittman, B. Hou, and M. C. Curras-Collazo Vasopressin Autoreceptors and Nitric Oxide-Dependent Glutamate Release Are Required for Somatodendritic Vasopressin Release from Rat Magnocellular Neuroendocrine Cells Responding to Osmotic Stimuli Endocrinology, February 1, 2007; 148(2): 479 - 489. [Abstract] [Full Text] [PDF]

				S. Ma, M. J. Shipston, D. Morilak, and J. A. Russell Reduced Hypothalamic Vasopressin Secretion Underlies Attenuated Adrenocorticotropin Stress Responses in Pregnant Rats Endocrinology, March 1, 2005; 146(3): 1626 - 1637. [Abstract] [Full Text] [PDF]

				M. Thibonnier, J. A. Preston, N. Dulin, P. L. Wilkins, L. N. Berti-Mattera, and R. Mattera The Human V3 Pituitary Vasopressin Receptor: Ligand Binding Profile and Density-Dependent Signaling Pathways Endocrinology, October 1, 1997; 138(10): 4109 - 4122. [Abstract] [Full Text] [PDF]